Skip to main content
Fig. 2 | BMC Medicine

Fig. 2

From: Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands

Fig. 2

Proportional reductions in IPD cases (top) and hospitalized NIPP cases (bottom) for different pneumococcal vaccination strategies for older adults (colors) compared to no pneumococcal vaccination, while varying the childhood vaccination strategy (columns). Results are based on a 65-year-old cohort, vaccinated at 70% vaccination coverage and followed over 15-year period. The main analysis estimate is depicted by the black line, while the distributions are based on 1000 Monte Carlo simulations in a probabilistic sensitivity analysis. 3xPPV23: PPV23 administered at years 0, 5, and 10; PCV15 + 3xPPV23: PCV15 administered at year 0 and PPV23 at years 1, 6, and 11; PCV20 + 3xPPV23: PCV20 administered at year 0 and PPV23 at years 1, 6, and 11. IPD, invasive pneumococcal disease; NIPP, non-invasive pneumococcal pneumonia; PCV, pneumococcal conjugate vaccine; PPV, pneumococcal polysaccharide vaccine

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us